Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API

AUTL
Autolus Therapeutics plc
stock NASDAQ ADR

At Close
Sep 15, 2025 3:59:54 PM EDT
1.32USD-4.710%(-0.06)3,996,565
1.31Bid   1.34Ask   0.03Spread
Pre-market
Sep 15, 2025 9:25:30 AM EDT
1.40USD+1.449%(+0.02)3,569
After-hours
Sep 15, 2025 4:50:30 PM EDT
1.32USD+0.380%(0.00)1,780
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 10, 2022
07:25AM EST  Autolus Therapeutics Announces Retirement Of Chief Financial Officer, Andrew J. Oakley   Benzinga
07:01AM EST  Autolus Therapeutics announces retirement of chief financial   GlobeNewswire Inc
07:00AM EST  - obe-cel has the potential to transform outcomes for adult ALL patients   GlobeNewswire Inc
Jan 5, 2022
07:00AM EST  Autolus Therapeutics plc(Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that they are scheduled to deliver a corporate presentation at the following virtual conferences:   GlobeNewswire Inc
Dec 13, 2021
07:00AM EST  - Obe-cel shows sustained durability of response with morphological EFS of 46% at 24 months in the ALLCAR19 study   GlobeNewswire Inc
Dec 6, 2021
07:00AM EST  Autolus Therapeutics announce new time for investor call to   GlobeNewswire Inc
Dec 3, 2021
09:57AM EST  Autolus Therapeutics Option Alert: Jan 21 $7.5 Calls Sweep (4) near the Ask: 400 @ $0.7 vs 29 OI; Ref=$6.0   Benzinga
Nov 15, 2021
07:00AM EST  Autolus Therapeutics announces the appointment of Dr. William D.   GlobeNewswire Inc
Nov 10, 2021
07:00AM EST  Autolus Therapeutics announces publication describing its small   GlobeNewswire Inc
Nov 9, 2021
10:55AM EST  Mid-Afternoon Market Update: eHealth Drops Following Q3 Results; Autolus Therapeutics Shares Gain   Benzinga
10:48AM EST  Mid-Day Market Update: Trade Desk Jumps After Upbeat Results; GT Biopharma Shares Slide   Benzinga
Nov 8, 2021
10:09AM EST  Mid-Morning Market Update: Markets Rise; Coty Posts Upbeat Earnings   Benzinga
05:33AM EST  Syncona Announced- Blackstone Life Science to invest $250M in Autolus; Shares of Autolus Up 36% Premarket   Benzinga
02:00AM EST  One of the largest private financings of a UK biotech company, and the largest from a single source continues Blackstone conviction in the country   GlobeNewswire Inc
Nov 4, 2021
09:28AM EDT  Autolus Therapeutics Will Present New Data AT American Society Of Hematology Meeting Dec. 11-13   Benzinga
Nov 3, 2021
09:15AM EDT  Autolus Therapeutics Q3 EPS $(0.47) Beats $(0.51) Estimate   Benzinga
09:10AM EDT  Earnings Scheduled For November 3, 2021   Benzinga
07:00AM EDT  Autolus Therapeutics plc(Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced its operational and financial results for the third quarter ended September 30, 2021.   GlobeNewswire Inc
Oct 25, 2021
07:00AM EDT  Autolus Therapeutics plc(Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its third quarter 2021 financial results and operational highlights before open of U.S. markets on Wednesday, November 3, 2021.   GlobeNewswire Inc
Sep 16, 2021
07:05AM EDT  Autolus Therapeutics Announces Planning Approval Has Been Granted To Build Manufacturing Facility In Stevenage, UK   Benzinga
07:00AM EDT  Autolus Therapeutics provides an update on its manufacturing   GlobeNewswire Inc
Sep 15, 2021
07:32AM EDT  Autolus Therapeutics Appoints John Johnson As Non-executive Chairman   RTTNews
07:17AM EDT  Autolus Therapeutics Announces The Appointment Of John H. Johnson As Non-Executive Chairman Of Its Board of Directors   Benzinga
07:00AM EDT  Autolus Therapeutics announces the appointment of John H. Johnson   GlobeNewswire Inc
Sep 2, 2021
07:00AM EDT  - Goldman Sachs Eleventh Annual Biotech Symposium on September 7- 2021 Virtual Wells Fargo Healthcare Conferenceon September 10 at 7.30am ET   GlobeNewswire Inc
Sep 1, 2021
07:11AM EDT  Autolus Therapeutics Announces Publication Of Obe-cel Phase 1 ALLCAR19 Data In Adults With Relapsed/ Refractory B-ALL In Journal Of Clinical Oncology   Benzinga
07:00AM EDT  Autolus Therapeutics announces publication of obe-cel (AUTO1)   GlobeNewswire Inc
Aug 9, 2021
07:00AM EDT  Autolus Therapeutics Announces Promising Innovative Medicine (PIM)   GlobeNewswire Inc
Aug 5, 2021
08:08AM EDT  The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO   Benzinga
07:38AM EDT  Autolus Therapeutics Q2 EPS $(0.47) Beats $(0.50) Estimate, Sales $138.00K Miss $190.00K Estimate   Benzinga
07:00AM EDT  Autolus Therapeutics plc(Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced its operational and financial results for the quarter ended June 30, 2021.   GlobeNewswire Inc
04:08AM EDT  Earnings Scheduled For August 5, 2021   Benzinga
Aug 2, 2021
11:50AM EDT  Shares of Autolus Therapeutics plc (AUTL) gained over 11% on Monday morning after the company announced a deal with Moderna for access to proprietary targeting technology from Autolus.   RTTNews
08:49AM EDT  Autolus Stock Jumps On Cancer mRNA Therapeutics Agreement With Moderna   Benzinga
07:08AM EDT  Autolus And Moderna Sign Option And License Agreement For Access To Proprietary Targeting Technology From Autolus   Benzinga
07:00AM EDT  Autolus and Moderna sign Option and License Agreement for access   GlobeNewswire Inc
Aug 1, 2021
11:19AM EDT  The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs   Benzinga
Jul 15, 2021
07:01AM EDT  Autolus Therapeutics plc(Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced the appointment of Edgar Braendle M.D., Ph.D., as chief development officer. Dr Braendle is joining Autolus executive team today and will lead the company's development organization.   GlobeNewswire Inc
Jul 8, 2021
07:01AM EDT  Autolus Therapeutics plc(Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its second quarter 2021 financial results and operational highlights before open of U.S. markets on Thursday, August 5, 2021.   GlobeNewswire Inc
Jun 15, 2021
07:11AM EDT  Autolus Therapeutics Announces Innovation Licensing And Access Pathway Designation For Obe-cel For R/r Adult B-cell ALL   RTTNews
07:06AM EDT  Autolus Therapeutics Receives Innovation Licensing and Access Pathway Designation From UK Medicines And Healthcare products Regulatory Agency For AUTO1   Benzinga
07:00AM EDT  Autolus Therapeutics Announces Innovation Licensing and Access   GlobeNewswire Inc
Jun 11, 2021
09:43AM EDT  Autolus Therapeutics' CAR T Cell Achieves 100% Complete Remission In Indolent B Cell Non-Hodgkin Cohort   Benzinga
07:05AM EDT  Autolus Therapeutics Highlights Presentation Of AUTO1 Data At European Hematology Association Virtual Congress 2021   Benzinga
07:00AM EDT  Obe-cel achieves 100% complete remission rate in a cohort of indolent B Cell Non-Hodgkin lymphoma patients with excellent CAR T engraftment, expansion, and persistence   GlobeNewswire Inc
May 25, 2021
07:04AM EDT  Autolus Therapeutics Highlights AUTO1 Publication In Nature Cancer   Benzinga
07:00AM EDT  Autolus Therapeutics plc(Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced a publication in Nature Cancer that gives new insight into the mechanism of long-term durability of effect in acute lymphoblastic leukemia (ALL) patients treated with AUTO1.   GlobeNewswire Inc
May 21, 2021
07:00AM EDT  Autolus Notice of Annual General Meeting (AGM) on Friday, June 18,   GlobeNewswire Inc
May 12, 2021
10:00AM EDT  AUTO1 achieves 100% complete remission rate in cohort of r/r Indolent Non- Hodgkin Lymphoma patients   GlobeNewswire Inc
08:57AM EDT  The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron   Benzinga
May 11, 2021
07:54AM EDT  The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings   Benzinga
May 7, 2021
07:40AM EDT  The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs   Benzinga
May 6, 2021
12:08PM EDT  Needham Maintains Buy on Autolus Therapeutics, Lowers Price Target to $21   Benzinga
07:49AM EDT  The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom   Benzinga
07:37AM EDT  Autolus Therapeutics Q1 EPS $(0.53) Beats $(0.60) Estimate   Benzinga
07:00AM EDT  Autolus Therapeutics plc(Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced its operational and financial results for the quarter ended March 31, 2021.   GlobeNewswire Inc
04:17AM EDT  Earnings Scheduled For May 6, 2021   Benzinga
Apr 26, 2021
07:00AM EDT  Autolus Therapeutics plc(Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its first quarter 2021 financial results and operational highlights before open of U.S. markets on Thursday, May 6, 2021.   GlobeNewswire Inc
Apr 22, 2021
11:21AM EDT  Autolus Therapeutics US Patent & Trademark Office Abstract For 'CHIMERIC ANTIGEN RECEPTOR'   Benzinga
Apr 20, 2021
07:08AM EDT  Autolus Therapeutics Receives ILAP Designation From UK MHRA For AUTO4   Benzinga
07:00AM EDT  Autolus Therapeutics Receives Innovation Passport and entry into   GlobeNewswire Inc
Apr 19, 2021
07:08AM EDT  Autolus Therapeutics Names Martin Murphy Non-executive Chairman Of Its Board   RTTNews
07:00AM EDT  Autolus Therapeutics plc(Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that Dr Martin Murphy was appointed as non-executive chairman of its Board of Directors, effective April 15, 2021.   GlobeNewswire Inc
Apr 1, 2021
04:01PM EDT  Autolus Therapeutics plc(Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that management will participate in 1x1s at investor conferences through April 2021.   GlobeNewswire Inc
08:49AM EDT  Autolus Therapeutics Receives PRIME Designation From EMA For AUTO1 For The treatment Of Adult ALL   Benzinga
08:46AM EDT  Autolus Therapeutics Receives PRIME designation for AUTO1 for the   GlobeNewswire Inc
Mar 29, 2021
08:09AM EDT  Autolus Therapeutics Highlights Updated Manufacturing Facility Strategy For Commercial Supply Of AUTO1   Benzinga
08:00AM EDT  - Autolus to expand on existing operations in the UK for commercial supply of AUTO1 resulting in a less capital-intensive commercial infrastructure strategy- Mutual agreement to terminate lease for the manufacturing and office facility at 9950 Medical Center Drive, Rockville, MD, resulting in a cash payment to Autolus   GlobeNewswire Inc
Mar 10, 2021
10:03AM EST  Benzinga's Top Ratings Upgrades, Downgrades For March 10, 2021   Benzinga
07:20AM EST  Redburn Downgrades Autolus Therapeutics to Neutral   Benzinga
Mar 4, 2021
07:17AM EST  Autolus Therapeutics Reports Fy20 EPS $(2.76) Up From $(2.88) YoY   Benzinga
07:00AM EST  Autolus Therapeutics plc(Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced its operational and financial results for the fourth quarter and full year ended December 31, 2020.   GlobeNewswire Inc
04:07AM EST  Earnings Scheduled For March 4, 2021   Benzinga
Mar 3, 2021
10:43AM EST  Autolus Therapeutics's Earnings: A Preview   Benzinga
Feb 24, 2021
07:00AM EST  Autolus Therapeutics to Present at the H.C.   GlobeNewswire Inc
Feb 12, 2021
04:01PM EST  Autolus Announces Closing of Public Offering and Full Exercise of   GlobeNewswire Inc
Feb 10, 2021
06:59AM EST  Autolus Therapeutics Raises $100M Via Equity   Benzinga
Feb 9, 2021
08:42PM EST  Autolus Announces Pricing of Public Offering   GlobeNewswire Inc
08:10AM EST  The Daily Biotech Pulse: Dynavax Poaches GSK Vaccine Exec, KalVista Jumps On Data Readout, Corcept Issues Negative Preannouncement   Benzinga
Feb 8, 2021
04:22PM EST  Autolus Announces $100M ADS Offering   Benzinga
04:19PM EST  Autolus Announces Proposed Public Offering in the United States   GlobeNewswire Inc
Feb 4, 2021
07:00AM EST  Autolus Therapeutics plc(Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its fourth quarter and full year 2020 financial results and operational highlights before open ofU.S.markets onThursday, March 4, 2021.   GlobeNewswire Inc
Jan 29, 2021
10:04AM EST  Benzinga's Top Ratings Upgrades, Downgrades For January 29, 2021   Benzinga
08:25AM EST  JP Morgan Downgrades Autolus Therapeutics to Neutral, Lowers Price Target to $9   Benzinga
Jan 7, 2021
08:02AM EST  10 Biggest Price Target Changes For Thursday   Benzinga
06:21AM EST  HC Wainwright & Co. Maintains Buy on Autolus Therapeutics, Lowers Price Target to $13   Benzinga
Jan 6, 2021
05:29AM EST  Autolus Therapeutics Says Will Reduce Headcount by~20%; Sasy Expects to Realize Cash Savings, on an Annualized Basis, of $15M Per Annum Once Operational Change Fully Implemented   Benzinga
04:07AM EST  Company prioritizes AUTO1, a potentially transformational treatment for Adult Acute Lymphoblastic Leukemia (ALL), with full data from the AUTO1-AL1 study expected in 2022Company intends to partner AUTO3, ahead of progressing into the next phase of developmentCompany adjusting its workforce and infrastructure footprint to align with AUTO1 prioritization   GlobeNewswire Inc
02:28AM EST  Autolus Decides To Focus On AUTO1 Programme; To Implement   RTTNews
Jan 4, 2021
07:00AM EST  Autolus Therapeutics plc(Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that management will participate in investor conferences through January 2021.   GlobeNewswire Inc
Dec 28, 2020
06:47AM EST  HC Wainwright & Co. Assumes Autolus Therapeutics at Buy, Announces Price Target of $19   Benzinga
Dec 7, 2020
04:11PM EST  Autolus Therapeutics Says In ALLCAR19 Trial, 1 Additional Patient Was Dosed, Who Died Due To Infectious Complications Assessed As Unrelated To AUTO1   Benzinga
12:06PM EST  Autolus Therapeutics Presents Additional Data On Its AUTO03 In The DLBCL During The 62 ASH Meeting   Benzinga
12:01PM EST  AUTO3 continues to show a differentiated product profile supporting outpatient administration   GlobeNewswire Inc
Dec 6, 2020
08:41AM EST  Week Ahead In Biotech: FDA To Decide On Emergency Use Of Pfizer's COVID Vaccine, Hematology Conference Presentations Pick Up Pace   Benzinga
Dec 5, 2020
03:01PM EST  Updated data from the ALLCAR study suggests AUTO1s potential for transformational activity in adult patients with r/r ALL   GlobeNewswire Inc
Nov 30, 2020
07:00AM EST  - Findings from the Phase 1 study provide evidence that AUTO6 induces clinical activity in this solid tumor setting without inducing on-target off-tumor toxicity   GlobeNewswire Inc
Nov 29, 2020
08:59AM EST  The Week Ahead In Biotech: Hematology Conference Gets Underway, Vanda And BioCryst Await FDA Decisions   Benzinga
Nov 25, 2020
09:52AM EST  Benzinga's Top Upgrades, Downgrades For November 25, 2020   Benzinga
09:47AM EST  Redburn Initiates Coverage On Autolus Therapeutics with Buy Rating   Benzinga
Nov 17, 2020
07:00AM EST  Autolus Therapeutics plc(Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that management will host an investor conference call to discuss AUTO1 and AUTO3 data presented at the American Society of Hematology (ASH) Virtual Congress 2020 and will also participate in the Jefferies Banking Conference:   GlobeNewswire Inc
Nov 5, 2020
07:09AM EST  Autolus Therapeutics Q3 EPS $(0.72) Misses $(0.71) Estimate   Benzinga
07:00AM EST  Autolus Therapeutics plc(Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced its operational and financial results for the third quarter ended September 30, 2020.   GlobeNewswire Inc
04:34AM EST  Earnings Scheduled For November 5, 2020   Benzinga
Nov 2, 2020
08:59AM EST  Morgan Stanley Maintains Equal-Weight on Rocket Companies, Lowers Price Target to $23   Benzinga
Oct 30, 2020
07:00AM EDT  Autolus Therapeutics plc(Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its third quarter 2020 financial results and operational highlights before open of U.S. markets on Thursday, November 5, 2020.   GlobeNewswire Inc
Sep 18, 2020
03:05AM EDT  Autolus Therapeutics presents additional data on AUTO3 in DLBCL   GlobeNewswire Inc
Sep 8, 2020
07:00AM EDT  Autolus Therapeutics plc(Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that management will host an investor conference call to discuss AUTO3 data presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 and to participate in Banking conferences through September:   GlobeNewswire Inc
Aug 6, 2020
09:14AM EDT  Autolus Therapeutics Earlier Reported Q2 EPS $(0.62) Beats $(0.71) Estimate, Sales $293.00K Miss $440.00K Estimate   Benzinga
07:00AM EDT  Autolus Therapeutics plc(Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced its financial and operational results for the second quarter ended June 30, 2020.   GlobeNewswire Inc
Aug 4, 2020
07:00AM EDT  Autolus announces changes to its Board and Management Team   GlobeNewswire Inc
Jul 31, 2020
09:36AM EDT  Benzinga's Top Upgrades, Downgrades For July 31, 2020   Benzinga
06:03AM EDT  JP Morgan Initiates Coverage On Autolus Therapeutics with Overweight Rating, Announces Price Target of $25   Benzinga
Jul 30, 2020
07:00AM EDT  Autolus Therapeutics plc(Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its second quarter 2020 financial results and operational highlights before open of U.S. markets on Thursday, August 6, 2020.   GlobeNewswire Inc
Jul 22, 2020
10:43AM EDT  Why Autolus Therapeutics Is Trading Higher Today   Benzinga
06:50AM EDT  SunTrust Robinson Humphrey Initiates Coverage On Autolus Therapeutics with Buy Rating, Announces Price Target of $38   Benzinga


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC